Our work aligns with emerging efforts to target SGs and post-translational modifications in cancer therapy, such as MPN-based SG inhibitors in hepatocellular carcinoma and G3BP2-targeted approaches in breast cancer, underscoring the translational potential of targeting stress response pathways [34, 43]. Here, G3BP2 is linked to cancer.